CROWN POINT — O.Y.E. Therapeutics, a clinical-stage pharmaceutical development company with a drug targeted at expediting emergence from anesthesia, has announced a successful pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration.

A pre-IND meeting provides an opportunity for a drug development company and the FDA to discuss the drug’s development plan and to obtain the agency’s guidance for clinical studies of the company’s new drug candidate.